Cantheon Capital

Oxford Cannabinoid Technologies Ltd., established in 2017 and based in Oxford, UK, is a biopharmaceutical company dedicated to researching, developing, and licensing cannabinoid-based compounds and therapies. Its primary focus lies in creating novel treatments for diseases with high unmet medical need, combining cannabinoid medicine with world-class scientific research and drug development. The company's therapeutic areas of interest include inflammatory diseases, oncology, neurological disorders, and pain management.

Psycheceutical is a biotech company developing patented delivery technology for psychedelic pharmaceutical medicines, focusing on safety and efficacy for neuropsychiatry and pain. Its delivery system uses next-generation Janus particles and novel methods to enable immediate and sustained drug delivery, with precise dosage control and reduced GI tract exposure and toxicity. A topical formulation applied at the back of the neck targets peripheral nerves to provide a direct path to neural tissue in the brain, enabling safer, more effective administration of psychedelic compounds.

Albert Labs is a biopharmaceutical company dedicated to developing innovative prescription medicines aimed at addressing unmet mental health needs. The organization employs advanced culture technology and natural extraction methods alongside a comprehensive regulatory strategy to enhance the development of mental health drugs. Albert Labs prioritizes solutions that follow an approved, fast-track clinical pathway, specifically utilizing Real World Evidence (RWE) studies, which have been effectively applied in areas such as oncology and the recent development of COVID-19 vaccines. The company is initially focused on commercializing its mycelium-based treatment, KRN-101, to meet urgent patient needs in the mental health sector.

Psyence is a biotechnology company specializing in the research and development of natural psilocybin for treating psychological trauma and related disorders such as anxiety, depression, PTSD, stress, grief, and bereavement. It focuses on these conditions within palliative care settings.

Zelira Therapeutics Limited is a bio-pharmaceutical company based in Perth, Australia, specializing in the development of cannabinoid-based formulations aimed at treating various medical conditions. The company conducts human clinical trials targeting insomnia, autism, and opioid reduction, while also engaging in pre-clinical research to explore the effects of cannabinoids on breast, brain, and pancreatic cancers. Additionally, Zelira is investigating the potential of cannabinoid formulations to address diabetes-associated cognitive decline. The company collaborates with CannPal Pty Ltd and St Vincent's Hospital on opioid reduction studies. Formerly known as Zelda Therapeutics Limited, it rebranded to Zelira Therapeutics Limited in December 2019.